.
MergerLinks Header Logo

Announced

Completed

Perrigo completed the acquisition of HRA Pharma from Astorg and Goldman Sachs Asset Management for $1.9bn.

Financials

Edit Data
Transaction Value£1,515m
Consideration TypeCash
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Private Equity

France

treatment development

pharmaceuticals

Pharmaceuticals

Majority

Friendly

Acquisition

Cross Border

Private

Single Bidder

Completed

Synopsis

Edit

Perrigo, a firm providing over-the-counter self-care and wellness solutions, completed the acquisition of HRA Pharma, a consumer healthcare company, from investment firms Astorg and Goldman Sachs Asset Management for $1.9bn. "With the addition of HRA and its talented leadership team, Perrigo would be a consumer self-care global leader that is poised to deliver top tier net sales growth and double-digit EPS growth in the near-term while concurrently expanding margins. The complementary geographic footprint of HRA to that of Perrigo would allow for significant and actionable synergies. And it is the totality of these factors that makes the combination of Perrigo and HRA strategically and financially compelling. It's literally a one-of-a-kind opportunity to simultaneously enhance our financial profile, while driving even greater value for consumers, shareholders and the communities in which we work and live," Murray S. Kessler, Perrigo CEO and President.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US